<DOC>
	<DOC>NCT01557023</DOC>
	<brief_summary>This trial will study the percentage of women with at least one occurrence of intracyclic bleeding (bleeding and/or spotting) during the cycles 2 and 3 of treatment with test or reference drug.</brief_summary>
	<brief_title>Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol</brief_title>
	<detailed_description />
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<criteria>Sign, initial and date the informed consent form; Female patients, with child bearing potential, aged 18 to 35 years; Have indication to receive progesterone and estrogenbased low oral hormone treatment for at least 7 cycles (approximately 7 months) for birth control; Be able to comply with the study protocol; Show normal result in cervicalvaginal cytology conducted up to 3 months before study enrollment or be willing to repeat the screening visit test, which result must also be normal; Be willing to use one of the study drugs Is pregnant or breastfeeding, suspecting to be or planning to get pregnant; Patients currently using oral contraceptives with drospirenone 3 mg/ ethynilestradiol 30 mcg or dianogest 2 mg/ ethynilestradiol 30 mcg. Have history of gynecologic surgery such as hysterectomy, total oophorectomy or tubal ligation; Smoke over 10 cigarettes a day; Have any severe comorbidities (at the investigator's criteria), including bowel inflammatory disease Have hypertension, showing at least one of the following conditions: Systolic pressure &gt;140 mm Hg or diastolic pressure &gt;90 mm Hg in sitting position; Current use of pharmacological treatment for hypertension; Show history or currently have venous or arterial thromboembolism; History of breast or genital cancer; Have obesity (BMI &gt;30 kg/m2); Have liver disease or changed lab values; Currently have dysplasia or malignancy in cervicalvaginal cytology; Concomitantly use CYP3A4 metabolizing drugs or drugs causing drug interaction with other study drugs; History of abortion one (1) month before study enrollment; History of childbirth or breastfeeding 3 months before study enrollment; Have hypersensitivity to any of the study drug components; Patients with longterm disability, who have undergone a major surgery or any surgery in legs or major traumatism in the last 6 months; Have current diagnosis of sexually transmitted disease; Have used injectable hormones 3 months before study enrollment; Have used hormone implant 6 months before study enrollment; Have participated in another clinical trial in the last 12 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>